View Item 

Show simple item record

Sex‐Specific Associations of Oral Anticoagulant Use and Cardiovascular Outcomes in Patients With Atrial Fibrillation
dc.contributor.authorPalamaner Subash Shantha, Ghanshyam
dc.contributor.authorMentias, Amgad
dc.contributor.authorInampudi, Chakradhari
dc.contributor.authorKumar, Anita A.
dc.contributor.authorChaikriangkrai, Kongkiat
dc.contributor.authorBhise, Viraj
dc.contributor.authorDeshmukh, Abhishek
dc.contributor.authorPatel, Nileshkumar
dc.contributor.authorPancholy, Samir
dc.contributor.authorHorwitz, Phillip A.
dc.contributor.authorMickelsen, Steven
dc.contributor.authorBhave, Prashant D.
dc.contributor.authorGiudici, Michael
dc.contributor.authorOral, Hakan
dc.contributor.authorVaughan Sarrazin, Mary S.
dc.date.accessioned2017-11-13T16:40:40Z
dc.date.available2018-10-02T19:49:01Zen
dc.date.issued2017-08
dc.identifier.citationPalamaner Subash Shantha, Ghanshyam; Mentias, Amgad; Inampudi, Chakradhari; Kumar, Anita A.; Chaikriangkrai, Kongkiat; Bhise, Viraj; Deshmukh, Abhishek; Patel, Nileshkumar; Pancholy, Samir; Horwitz, Phillip A.; Mickelsen, Steven; Bhave, Prashant D.; Giudici, Michael; Oral, Hakan; Vaughan Sarrazin, Mary S. (2017). "Sex‐Specific Associations of Oral Anticoagulant Use and Cardiovascular Outcomes in Patients With Atrial Fibrillation." Journal of the American Heart Association (8): n/a-n/a.
dc.identifier.issn2047-9980
dc.identifier.issn2047-9980
dc.identifier.urihttps://hdl.handle.net/2027.42/139084
dc.publisherWiley Periodicals, Inc.
dc.subject.othermyocardial infarction
dc.subject.otheratrial fibrillation
dc.subject.otherheart failure
dc.subject.othermortality
dc.subject.othersex
dc.titleSex‐Specific Associations of Oral Anticoagulant Use and Cardiovascular Outcomes in Patients With Atrial Fibrillation
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139084/1/jah32481-sup-0001-TableS1.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139084/2/jah32481.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139084/3/jah32481_am.pdf
dc.identifier.sourceJournal of the American Heart Association
dc.identifier.citedreferencePatel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883 – 891.
dc.identifier.citedreferencePokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & Investigators; ROCKET AF Steering Committee Investigators. Cause of death and predictors of all‐cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. J Am Heart Assoc. 2016; 5: e002197. DOI: 10.1161/JAHA.115.002197.
dc.identifier.citedreferenceStewart S, Hart CL, Hole DJ, McMurray JJ. A population‐based study of the long‐term risks associated with atrial fibrillation: 20‐year follow‐up of the Renfrew/Paisley study. Am J Med. 2002; 113: 359 – 364.
dc.identifier.citedreferenceFriberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort‐Study of Atrial Fibrillation (SCAF). Eur Heart J. 2007; 28: 2346 – 2353.
dc.identifier.citedreferenceVioli F, Soliman EZ, Pignatelli P, Pastori D. Atrial fibrillation and myocardial infarction: a systematic review and appraisal of pathophysiologic mechanisms. J Am Heart Assoc. 2016; 5: e003347. DOI: 10.1161/JAHA.116.003347.
dc.identifier.citedreferenceJanuary CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014; 130: 2071 – 2104.
dc.identifier.citedreferenceGómez‐Outes A, Lagunar‐Ruíz J, Terleira‐Fernández AI, Calvo‐Rojas G, Suárez‐Gea ML, Vargas‐Castrillón E. Causes of death in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2016; 68: 2508 – 2521.
dc.identifier.citedreferenceAmsterdam E, Wenger N, Brindis R, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ; ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non‐ST‐elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guideline. Circulation. 2014; 130: e344 – e426.
dc.identifier.citedreferenceChatterjee S, Sharma A, Uchino K, Biondi‐Zoccai G, Lichstein E, Mukherjee D. Rivaroxaban and risk of myocardial infarction: insights from a meta‐analysis and trial sequential analysis of randomized clinical trials. Coron Artery Dis. 2013; 24: 628 – 635.
dc.identifier.citedreferenceLauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G. Effectiveness and safety of dabigatran and warfarin in real‐world US patients with non‐valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc. 2015; 4: e001798. DOI: 10.1161/JAHA.115.001798.
dc.identifier.citedreferenceDouxfils J, Buckinx F, Mullier F, Minet V, Rabenda V, Reginster JY, Hainaut P, Bruyère O, Dogné JM. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all‐cause mortality: a systematic review and meta‐analysis of randomized controlled trials. J Am Heart Assoc. 2014; 3: e000515. DOI: 10.1161/JAHA.113.000515.
dc.identifier.citedreferencePalamaner Subash Shantha G, Bhave P, Girotra S, Hodgson‐Zingman D, Mazur A, Giudici M, Chrischilles E, Vaughan Sarrazin M. Sex specific comparative effectiveness of oral anticoagulants in elderly patients with newly diagnosed atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2017; 10: 4. pii: e003418.
dc.identifier.citedreferenceEllis ER, Culler SD, Simon AW, Reynolds MR. Trends in utilization and complications of catheter ablation for atrial fibrillation in Medicare beneficiaries. Heart Rhythm. 2009; 6: 1267 – 1273.
dc.identifier.citedreferenceElixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998; 36: 8 – 27.
dc.identifier.citedreferenceChen JY, Zhang AD, Lu HY, Guo J, Want FF, Li ZC. CHADS2 versus CHA2DS2‐VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta‐analysis. J Geriatr Cardiol. 2013; 10: 258 – 266.
dc.identifier.citedreferencePisters R, Lane DA, Niewlaat R, deVos CB, Crijns HJ, Lip GY. A novel user‐friendly score (HAS‐BLED) to assess 1‐year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138: 1093 – 1100.
dc.identifier.citedreferenceGagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011; 64: 749 – 759.
dc.identifier.citedreferenceRassen JA, Shelat AA, Franklin JM, Glynn RJ, Solomon DH, Schneeweiss S. Matching by propensity score in cohort studies with three treatment groups. Epidemiology. 2013; 24: 401 – 409.
dc.identifier.citedreferenceAustin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samples. Stat Med. 2009; 28: 3083 – 3107.
dc.identifier.citedreferenceMega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook‐Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9 – 19.
dc.identifier.citedreferenceLarsen TB, Rasmussen LH, Skjoth F, Due KM, Callréus T, Rosenzweig M, Lip GY. Efficacy and safety of dabigatran etexilate and warfarin in “real‐world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013; 61: 2264 – 2273.
dc.identifier.citedreferenceHarenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta‐analysis. Int Angiol. 2012; 31: 330 – 339.
dc.identifier.citedreferenceChan YH, Kuo CT, Yeh YH, Chang SH, Wu LS, Lee HF, Tu HT, See LC. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2016; 68: 1389 – 1401.
dc.identifier.citedreferenceZannad F, Stough WG, Regnault V, Gheorghiade M, Deliargyris E, Gibson CM, Agewall S, Berkowitz SD, Burton P, Calvo G, Goldstein S, Verheugt FW, Koglin J, O’Connor CM. Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. Int J Cardiol. 2013; 167: 1772 – 1782.
dc.identifier.citedreferenceBorissoff JI, Spronk HM, Heeneman S, ten Cate H. Is thrombin a key player in the ‘coagulation‐atherogenesis’ maze? Cardiovasc Res. 2009; 82: 392 – 403.
dc.identifier.citedreferenceZannad F, Greenberg B, Dleland JG, Gheorghiade M, van Veldhuisen DJ, Mehra MR, Anker SD, Byra WM, Fu M, Mills RM. Rationale and design of a randomized, double‐blind, event‐driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial. Eur J Heart Fail. 2015; 17: 735 – 742.
dc.identifier.citedreferenceGraham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, Southworth MR, Wei Y, Liao J, Goulding MR, Mott K, Chillarige Y, MaCurdy TE, Worrall C, Kelman JA. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016; 176: 1662 – 1671.
dc.identifier.citedreferenceDiaz‐Garzon J, Sandoval Y, Smith SW, Love S, Schulz K, Thordsen SE, Johnson BK, Driver B, Jacoby K, Carlson MD, Dodd KW, Moore J, Scott NL, Bruen CA, Hatch R, Apple FS. Discordance between ICD‐coded myocardial infarction and diagnosis according to the universal definition of myocardial infarction. Clin Chem. 2017; 63: 415 – 419.
dc.identifier.citedreferenceKociol RD, Pang PS, Gheorghiade M, Fonarow GC, O’Connor CM, Felker GM. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010; 56: 1071 – 1078.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jah32481-sup-0001-TableS1.pdf
Size:
158.9KB
Format:
PDF
View/Open
Name:
jah32481.pdf
Size:
1.140MB
Format:
PDF
View/Open
Name:
jah32481_am.pdf
Size:
247.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.